These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37095618)

  • 1. Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Kim MC; Kwon SY; Choi JE; Kang SH; Bae YK
    J Breast Cancer; 2023 Apr; 26(2):105-116. PubMed ID: 37095618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.
    Luo Y; Gao Y; Niu Z; Zhang J; Liu Z; Zhang Y; Shen S; Jiang Y; Xiao M; Zhu Q
    Quant Imaging Med Surg; 2024 May; 14(5):3519-3533. PubMed ID: 38720854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
    Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
    Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
    Shibata A; Tamura N; Kinowaki K; Nishikawa A; Tanaka K; Kobayashi Y; Ogura T; Tanabe Y; Kawabata H
    Breast Cancer; 2024 Nov; 31(6):1018-1027. PubMed ID: 39020239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Oncotype DX Recurrence Score Based on Systematic Evaluation of Ki-67 Scores in Hormone Receptor-Positive Early Breast Cancer.
    Kim JM; Cho EY
    J Breast Cancer; 2024 Jun; 27(3):201-214. PubMed ID: 38951111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
    Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
    Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Orucevic A; Bell JL; McNabb AP; Heidel RE
    Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
    Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
    Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
    Ünal Ç; Özmen T; İlgün AS; Ordu Ç; Özkurt E; Ak N; Alço G; Erdoğan İyigün Z; Kurt S; Duymaz T; Öztürk MA; Elbüken Çelebi F; Yararbaş K; Soybir G; Aktepe F; Özmen V
    Breast Cancer (Dove Med Press); 2023; 15():659-669. PubMed ID: 37674872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
    Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
    Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
    Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
    Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer.
    Song R; Lee DE; Lee EG; Lee S; Kang HS; Han JH; Lee KS; Sim SH; Chae H; Kwon Y; Woo J; Jung SY
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre.
    Davey MG; Ryan ÉJ; Abd Elwahab S; Elliott JA; McAnena PF; Sweeney KJ; Malone CM; McLaughlin R; Barry MK; Keane MM; Lowery AJ; Kerin MJ
    Breast J; 2021 Jun; 27(6):521-528. PubMed ID: 33709552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
    Mooghal M; Khan MAA; Samar MR; Shaikh H; Valimohammad AT; Idrees R; Abdul Rashid Y; Sattar AK
    Breast Cancer (Auckl); 2024; 18():11782234241255211. PubMed ID: 38779417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attempt to Substitute the Oncotype DX Breast Recurrence Score
    Nozaki Y; Horimoto Y; Semba R; Ueki Y; Ishizuka Y; Onagi H; Hayashi T; Kawate T; Ishikawa T; Watanabe J
    Cancer Diagn Progn; 2024; 4(4):464-469. PubMed ID: 38962532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer.
    Alshamsan B; Alshibany A; Elshenawy MA; Badran A; Elhassan T; Ajarim D; Alsayed A; Suleman K; Al-Tweigeri T
    Cancer Manag Res; 2021; 13():9411-9420. PubMed ID: 35002318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.